Korro Bio, Inc.
General ticker "KRRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $174.1M (TTM average)
Korro Bio, Inc. does not follow the US Stock Market performance with the rate: -0.5%.
Estimated limits based on current volatility of 5.7%: low 12.95$, high 14.52$
Factors to consider:
- Total employees count: 58 (-44.2%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Regulatory and compliance, Operating losses persist, Market competition, Manufacturing capacity limits, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.77$, 15.90$]
- 2026-12-31 to 2027-12-31 estimated range: [3.52$, 11.93$]
Financial Metrics affecting the KRRO estimates:
- Positive: with PPE of -0.6 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: Inventory ratio change, % of 5.67 > 0.80
- Positive: Investing cash flow per share per price, % of 58.04 > -0.60
- Negative: negative Industry operating cash flow (median)
- Positive: 42.57 < Shareholder equity ratio, % of 45.32 <= 64.23
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term KRRO quotes
Long-term KRRO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $2.27MM | $6.39MM |
| Operating Expenses | $84.53MM | $94.18MM | $128.25MM |
| Operating Income | $-84.53MM | $-91.91MM | $-121.86MM |
| Non-Operating Income | $3.39MM | $8.47MM | $5.23MM |
| R&D Expense | $57.25MM | $63.64MM | $65.58MM |
| Income(Loss) | $-81.14MM | $-83.44MM | $-116.62MM |
| Taxes | $0.03MM | $0.14MM | $0.64MM |
| Net Income(Loss)* | $-81.17MM | $-83.58MM | $-117.26MM |
| Stockholders Equity | $169.91MM | $160.41MM | $51.44MM |
| Assets | $221.66MM | $226.24MM | $113.51MM |
| Operating Cash Flow | $-67.28MM | $-60.07MM | $-78.56MM |
| Capital expenditure | $7.84MM | $17.90MM | $0.52MM |
| Investing Cash Flow | $11.16MM | $-123.35MM | $43.99MM |
| Financing Cash Flow | $187.76MM | $69.36MM | $0.69MM |
| Earnings Per Share** | $-53.09 | $-9.37 | $-12.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.